{"id":9365,"date":"2021-04-22T15:43:00","date_gmt":"2021-04-22T22:43:00","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=9365"},"modified":"2021-04-23T15:43:50","modified_gmt":"2021-04-23T22:43:50","slug":"safety-and-efficacy-of-single-dose-ad26-cov2-s-vaccine-against-covid-19","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/22\/safety-and-efficacy-of-single-dose-ad26-cov2-s-vaccine-against-covid-19\/","title":{"rendered":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">The SARS-CoV-2 single-dose adenovirus vector vaccine Ad26.COV2.S (Johnson &amp; Johnson) protected against moderate to severe-critical COVID-19 \u226514 days after administration with 66.9% efficacy (95% CI: 59-73.4%) in a randomized, double-blind placebo-controlled phase 3 trial. 116 cases occurred among those receiving the vaccine (n=19,691) vs 348 cases in the placebo group (n=19,691). Efficacy \u226528 days after administration was 66.1% (66 vs 193 cases; 95% CI: 55-74.8%). Vaccine efficacy against severe-critical COVID-19 was 76.7% at onset \u226514 days and 85.4% at onset \u226528 days.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Among participants in South Africa where 94.5% (86 of 91) of cases had the B.1351 variant, vaccine efficacy was 52% at onset \u226514 days and 64% at onset \u226528 days against moderate to severe-critical COVID-19. Efficacy against severe-critical COVID-19 was 73.1% at onset \u226514 days and 81.7% at onset \u226528 days.<\/span><\/li>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">While serious adverse events were balanced across the vaccine and placebo groups, imbalance towards the vaccine group were observed for thromboembolic events (11 vs. 3 cases), seizure (4 vs 1 cases), and tinnitus (6 vs 0 cases). The authors could not determine a causal relationship with the vaccine.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Sadoff et al.\u00a0(Apr 21, 2021). Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. New England Journal of Medicine. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2101544\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1056\/NEJMoa2101544<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The SARS-CoV-2 single-dose adenovirus vector vaccine Ad26.COV2.S (Johnson &amp; Johnson) protected against moderate to severe-critical COVID-19 \u226514 days after administration with 66.9% efficacy (95% CI: 59-73.4%) in a randomized, double-blind placebo-controlled phase 3 trial. 116 cases occurred among those receiving the vaccine (n=19,691) vs 348 cases in the placebo group (n=19,691). Efficacy \u226528 days after&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/22\/safety-and-efficacy-of-single-dose-ad26-cov2-s-vaccine-against-covid-19\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[33],"topic":[31],"class_list":["post-9365","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccines","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9365","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=9365"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9365\/revisions"}],"predecessor-version":[{"id":9366,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9365\/revisions\/9366"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=9365"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=9365"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=9365"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=9365"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}